DOWNLOAD LOTTERY RESULT HERE:
[RESULT PUBLISHED ON: 15TH MAY, 2016 | 12:50 P.M.]
The Bangladesh Securities Exchange Commission (BSEC) approved IPO “ACME Laboratories Limited” on Tuesday 23 February 2016 on their 567 nos Board Meeting presided by BSEC Chairman Prof. M Khairul Hossain to raise Tk. 409.60 crore by offloading 5 crore shares at a price of Tk. 77 to Tk. 85.20 each share. The Commission approved the IPO under the latest public issue rules although the company conducted book-building price bidding under the outdated public issue rules. The BSEC on 7 December 2015 allowed ACME to conduct eligible institutional investors bidding under the book building method of public issue rules 2006, which became obsolete after 31 December 2015 after the newly amended public issue rules came into action.
ACME will offload 5.0 crore ordinary shares of Tk. 10 each of which 2.50 crore shares have been kept for institutional investors and 50 lac for mutual funds as per the bidding of EIIs, the cut-off price of ACME shares stands at Tk. 85.20 each. but newly enacted public issue rules, decided to offer ACME’s IPO shares to individual investors at 10 percent discount of cut-off price which was set by the bidding of the EIIs, which will be allotted to general investors at Tk. 77 each. Company Information, IPO Application Form, Prospectus & Result is given below:
The ACME Laboratories Limited is the oldest pharmaceutical company in Bangladesh. It is the part of ACME group of company. In 1954, ACME was founded modestly as a Proprietorship Firm at Narayangonj by the great visionary, the Late Hamidur Rahman Sinha, with a very noble and holistic motto to ensure health, vigour and happiness for all. In 1976, the ACME was converted into a Private Limited Company for giving it perpetual shape and eventually in 1983, the ACME’s plant was transferred to Dhamrai on the outskirts of the capital about forty kilometers away from Dhaka City after making BMRE.
The ACME Laboratories Limited is a leading company for manufacturing world-class and top-quality pharmaceutical products in Bangladesh. Currently producing more than 500 products in different dosage forms covering broader therapeutic categories which include anti-infective, cardiovascular, anti-diabetics, gastrointestinal, CNS, respiratory disease etc. among many others. The success in the local market prompted us to explore the international market and over the years we gained a firm presence in South East Asia, Africa and Central America and continuously discovering new horizons to improve the quality of life for patients, to further the success of our customers and to help meet global challenges.
ACME has achieved ISO Certification to ISO 9001:2008 in the year 2009 and relentlessly working for overseas accreditation to put an extra hold in our export potentials as well as local brand image. Currently, we are closely working under the supervision of European consultants eyeing for UK MHRA certification and expect to achieve by the middle of 2016.
MISSION, VISION & CORE VALUES:
MISSION: ACME holistic approach is to ensure Health, Vigour and Happiness for all by manufacturing ethical drugs and medicines of the highest quality at an affordable price and expanding in the local and global market. ACME view it selves as partners with the doctors, healthcare professionals, all other customers, ACME employees and harmonize with environmental issues.
VISION: To ensure Health, Vigour and Happiness for all.
CORE VALUES: The Company values are the measure of our thinking and actions. They are the core of what ties us together in the past, present and future. We do business on the basis of common values. Our success is based on customer focus, team spirit, desire to win, pro-activity, integrity and excellence. These values determine our actions in our daily dealing with customers and business partners as well as in our teamwork and our collaboration with each other.
ACME’s production covers a wide range of Pharmaceutical formulations in different dosage forms. These include Oral Liquid, Tablets, Capsules, Injectables, Cream & Ointment, Metered Dose Inhaler (MDI), Dry Powder Inhaler (DPI), and Suppository. Besides manufacturing human medicine, ACME produces quality veterinary drugs. ACME’s present product portfolio is enriched by herbal & nutraceuticals and Ayurvedic products as well, which is now in the juvenile stage. At present, the total number of the produces exceeds 400 and more and more new products are being added in the portfolio every year.
Pharmaceutical industry is dynamic in nature and heavily driven by up to date knowledge and technology. As one of the leading pharmaceutical firm of the country, ACME established cutting edge technologies which comply with WHO cGMP, UK MHRA, US FDA and European Standards.
The facilities are unique for Integrated building management system, World-class structural design, Dust –free environment, Well-designed HVAC system, Zero cross-contamination, Total compliance as per GMP, Vacuum transfer close system, Different storage conditions, High-tech chemical & microbiological laboratories, Modern R&D facility, Maintenance by NIST, Most up-to-date purified water generation plant and Fire management system. [Source: Web site]
ACME LABORATORIES Limited ADDRESS:
ACME’s modernized plant is located at Dhamrai, about 40 km N.W. of Dhaka, the capital of Bangladesh.
Plant Address: Dhamrai, Dhaka, Bangladesh
Phone: +88 02 7730142, +88 02 7730816-7, +88 02 7730881-2
Fax: +88 02 7730141
Email: [email protected]
Corporate Office: ACME Laboratories Limited Court de la ACME
1/4, Mirpur Road, Kallayanpur,
Dhaka 1207, Bangladesh.
Phone: +88 02 9004194-6, +88 02 9005620
Fax: +88 02 9016872, +88 02 9032475, +88 02 9016515
Web Address: www.acmeglobal.com
COMPANY EPS & NAV PER SHARE:
The Company’s last five years (01-07-2010 to 30-06-2015) weighted average earning per shares (EPS) was Tk. 4.07 and Tk. 5.70 for the year ended on 30 June 2015. Net Assets Value (NAV) per share is Tk. 70.37 for the year ended on 30 June 2015.
ICB Capital Management is the issue manager of the company while Prime Capital Management is the registrar to the issue.
WHY PUBLIC OFFERING:
As per newly amended public issue rules Bangladesh Securities Exchange Commission (BSEC) approved to offer ACME’s of the 5 crore IPO shares, 2.50 crore will be allocated for EIIs worth Tk. 2,130.00 million, 50 lac for mutual fund worth Tk.426.00 million and rest 2 crore shares will be offered to the general, affected and NRB investors worth Tk. 1540.00 million. ACME Laboratories will use the IPO fund (Tk. 4,096.00 million) in implementing three new projects and to meet from IPO proceeds.
NOS. OF SHARE OFFER For EII: 25,000,000
NOS. OF SHARE OFFER For Mutual Fund: 5,000,000
NOS. OF SHARE OFFER For INDIVIDUAL INVESTORS: 20,000,000
Total VALUE OF IPO: Tk. 4,096,000,000/=
INDIVIDUAL INVESTORS IPO VALUE: Tk. 1,540,000,000/=
FACE VALUE: Tk. 10/=
PREMIUM VALUE: Tk. 67/=
MARKET LOT: 100
TOTAL PRICE: TK. 7,700.-
SHARE ALLOTMENT: 25 million for EII= 250,000 lot, 5million for Mutual Fund =50,000 and Individual Investors =300,000 lot.
20% of the securities for general public shall be reserved for Affected Investors.
** The Company will collect IPO money through BSEC new rules and the new rule is “BROKER HOUSE SHOULD COLLECT IPO MONEY ONLY”.
ACME Laboratories Limited subscription start from 11 April 2016 cut of date 21 April 2016 [Including NRB].
ACME IPO FORM DOWNLOAD HERE:
ACME LABORATORIES Limited: PROSPECTUS
THANK YOU FOR VISITING DORMANTLIFE.COM.
Incoming search terms:
the acme lab ltd monogaram